BLRX — BioLineRx Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1498403 ·
Israel
Last close
$3.02
Market Cap
$13.14M
52W High
$3.95
52W Low
$2.15
ADV30
80,328
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 477,000 | 382,000 | -3,004,000 | -1,601,000 | 38,797,000 | 2,504,000 | 17,962,000 |
| Dec 2025 | 194,000 | 154,000 | -3,386,000 | -1,385,000 | 40,905,000 | 3,250,000 | 17,560,000 |
| Sep 2025 | 427,000 | 343,000 | -2,207,000 | -977,000 | 39,804,000 | 7,914,000 | 20,271,000 |
| Jun 2025 | 304,000 | 232,000 | -2,303,000 | -3,940,000 | 43,267,000 | 7,189,000 | 23,195,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,074,000
Investing CF
$-8,545,000
Financing CF
$8,884,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-401,002,000
Inventory
$2,148,000
Receivables
$456,000
ST Investments
$17,626,000
EBIT TTM
$-775,000
Pretax Income TTM
$-2,026,000
Interest Exp TTM
$1,251,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,402,000
EBITDA
$-10,750,000
Free Cash Flow
$-5,490,125
Enterprise Value
$9,150,640
Total Cash
$17,353,000
Total Debt
$9,070,000
Shares Out
4,351,357
Trailing EPS
$0.00
Book Value
$3.60
ROE
-46.7%
ROA
-16.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,180,000 | -10,287,000 | -1,175,000 | 40,905,000 | 17,560,000 | — | -8,074,000 |
| Dec 2024 | 28,940,000 | -19,152,000 | -9,221,000 | 38,906,000 | 25,445,000 | — | -43,873,000 |
| Dec 2023 | 4,800,000 | -42,991,000 | -60,614,000 | 63,925,000 | 50,702,000 | — | -22,608,000 |
| Dec 2022 | 0 | -29,157,000 | -24,951,000 | 76,384,000 | 25,543,000 | — | -26,240,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | $13.27M | $0.84 | — |
| BFRG | BullFrog AI Holdings, Inc. | $12.93M | $0.70 | — |
| COCP | Cocrystal Pharma, Inc. | $13.39M | $0.97 | — |
| BIVI | BIOVIE INC. | $13.50M | $1.79 | — |
| GDTC | CytoMed Therapeutics Ltd | $12.78M | $1.08 | — |
News headlines (Yahoo Finance, 1h cache)
BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-06-03 01:01 · Yahoo
BLRX: First Quarter 2026 Results
2026-05-28 15:17 · Yahoo
BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)
2026-05-27 11:53 · Yahoo
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-27 11:00 · Yahoo
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
2026-05-22 11:00 · Yahoo
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
2026-05-20 11:00 · Yahoo
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
2026-05-19 11:00 · Yahoo
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-04-28 11:00 · Yahoo
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
2026-04-08 06:30 · Yahoo
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-03-26 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.